• Company
• Companies produced KRW 66.7B finished drugs a year
• by Chon, Seung-Hyun Jan 24, 2025 05:52am

• Company
• Will long-acting HIV treatment be included in the reimb list
• by Eo, Yun-Ho Jan 24, 2025 05:52am

• InterView
• Approval called for drug switching in atopic dermatitis
• by Whang, byung-woo Jan 24, 2025 05:51am

• Policy
• 'Lixiana' patent expires next year, good news for
• by Lee, Hye-Kyung Jan 24, 2025 05:51am

• Policy
• Hokunalin Patch has been removed from Korea’s reimbursement
• by Lee, Tak-Sun Jan 24, 2025 05:51am

• Policy
• Govt plans to expand CDMO capacity by 2.5 times
• by Lee, Hye-Kyung Jan 24, 2025 05:51am

• Company
• The era of compound management for obesity
• by Whang, byung-woo Jan 23, 2025 05:54am

• Policy
• If atrial fibrillation develops, Rx 'Omega-3' API
• by Lee, Hye-Kyung Jan 23, 2025 05:54am

• Policy
• MFDS approves immune thrombocytopenia drug Tavalisse
• by Lee, Hye-Kyung Jan 23, 2025 05:54am

• Company
• MET inhibitor Tepmetko enters last stage to reimb in KOR
• by Eo, Yun-Ho Jan 23, 2025 05:54am